Combo Products Will Grow More Dependent On Drug Function – Guidant Exec
This article was originally published in The Gray Sheet
Executive Summary
Product stability, drug release rates and other factors unique to pharmaceuticals will grow increasingly relevant to device firms developing combination products, according to Guidant VP-Endovascular Operations Richard Rapoza, PhD
You may also be interested in...
Will Guidant Return To Pharma Roots After 10 Years As Stand-Alone Entity?
Guidant's cardiac surgery device and guiding catheter segments offer an attractive fit with Johnson & Johnson, though ICD market access and drug-eluting stent synergies would be the true drivers of any merger
Will Guidant Return To Pharma Roots After 10 Years As Stand-Alone Entity?
Guidant's cardiac surgery device and guiding catheter segments offer an attractive fit with Johnson & Johnson, though ICD market access and drug-eluting stent synergies would be the true drivers of any merger
J&J Building Competitive Advantages In CMS Skills And Drug-Device Combos
Cordis began working with the Centers for Medicare & Medicaid Services on reimbursement for Cypher as soon as the sirolimus stent entered clinical trials, Cordis World Wide Group Chairman Bob Croce told the Wharton Health Care Business Conference Feb. 20 in Philadelphia